Evidence map›Paper›PMID 30510922›Full record

ArticleJournal of hepatocellular carcinoma2018

Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study).

Hamdy A Azim, Ashraf Omar, Hesham Atef, Heba Zawahry, Mohamed K Shaker, Ah Kamel Abdelmaksoud, Mohamed EzzElarab, Omar Abdel-Rahman, Mohamed Ismail, Loay Kassem and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Characterization of metabolic landscape in hepatocellular carcinoma.World journal of gastrointestinal oncology · 2021
    Review
  10. Article
  11. Review
  12. Review
  13. Targeted therapy for hepatocellular carcinoma.Signal transduction and targeted therapy · 2020
    Review
  14. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2020
    Review
  15. Exosomes and Hepatocellular Carcinoma: From Bench to Bedside.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Hamdy A AzimDepartment of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt, Azimonc@cairocure.com, Kassem@cairocure.com.
Ashraf OmarDepartment of Gastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Hesham AtefDepartment of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt, Azimonc@cairocure.com, Kassem@cairocure.com.
Heba ZawahryDepartment of Medical Oncology, National Cancer Institute, Cairo, Egypt.
Mohamed K ShakerTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ah Kamel AbdelmaksoudDepartment of Diagnostic and Intervention Radiology, Cairo University, Cairo, Egypt.
Mohamed EzzElarabNational Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Omar Abdel-RahmanClinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed IsmailClinical Oncology Department, Cairo Oncology Center, Cairo, Egypt.
Loay KassemDepartment of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt, Azimonc@cairocure.com, Kassem@cairocure.com.
Imam WakedInstitute of Liver Disease, Menoufiya University, Menoufiya, Egypt.
Cairo University · EGAin Shams University · EGChildren Cancer Hospital · EGMenoufia University · EGNational Water Research Center · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhase II trials found that tegafur-uracil (UFT) is an effective drug in hepatocellular carcinoma (HCC), while preclinical data suggested that its combination with sorafenib may have a promising activity. Our Phase II randomized trial aimed to evaluate efficacy and tolerability of sorafenib plus UFT vs sorafenib in advanced HCC.

methodsPatients with advanced HCC, with no prior systemic therapy, were randomized to receive either UFT at 125 mg/m

resultsBetween March 2012 and March 2014, 76 eligible patients - out of 143 preplanned - were randomized. The study was terminated early because of futility. This is the final analysis of the study, after a median follow-up of 10.2 months and death of 86% of randomized patients (n=64). Median TTP was 7.5 months and 8.2 months in arms 1 and 2 respectively (HR: 1.07; 95% CI, 0.52-2.22;

conclusionIn patients with advanced HCC, adding UFT to sorafenib is feasible, but it did not improve efficacy outcome over sorafenib monotherapy.

Indexed as

advanced hepatocellular carcinomaEgyptsorafenibtegafur/uracil

Identifiers

PMID30510922
PMCPMC6250115
OpenAlexW2900991348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.